This analysis shows that the residual cancer burden index predicts outcomes in breast cancer subtypes, highlighting its potential as a prognostic tool.
The use of neoadjuvant chemotherapy (NAC) has improved outcomes in breast cancer (BC). The residual cancer burden index (RCB) predicts prognosis. This study evaluated RCB as a prognosticator in BC subtypes treated with NAC.
No takes yet. Share an insight, caveat, or question.
Valente et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: